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Revealed by Cyclosporin A Treatment
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Cyclosporin A (CsA) inhibits the development of mature thymocytes from their
CD4 CD8 precursors, but may allow autoreactive cells to mature. Using 3-color flow
cytometry, we have followed the progressive development of thymocytes, including
potentially autoreactive cells, during CsA treatment. Numbers of CD4 +CD8+CD3high
thymocytes dropped immediately, suggesting that the generation of these mature thymo-
cyte precursors, normally dependent upon positive selection, was inhibited by CsA.
Numbers of CD4 CD8- thymocytes also declined rapidly, but CD4- CD8 thymocytes
were unaffected lfor 2 days, suggesting that the mature single-positive subsets are not
symmetrically derived from a common GsA-sensitive precursor. An exceptional subset of
CD8 SP thymocytes, expressing CD45RA, did not respond to CsA for about 10 days,
indicating that they are distantly derived from a CsA-sensitive precursor. Apoptosis of
TCR-V,83 thymocytes caused by Mtv-6, quantified according to the down-regulation of
CD4 and CD8 on immature thymocytes, was partially inhibited by CsA, to maximal effect
within 24 hours. This did not, however, facilitate their development into mature thymo-
cytes.
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INTRODUCTION
Cyclosporin A (CsA) is an immunosuppressive drug
known to influence the development of thymocytes.
At a molecular level, CsA target sites have been
identified as cyclophilin and calcineurin (Fischer et
al., 1989; Takahashi et al., 1989; Liu et al., 1991;
Clipstone and Crabtree, 1992; O’Keefe et al., 1992).
Their significance at stages of T-cell development,
however, remains to be determined. Nevertheless,
treatment with CsA presents a useful tool with
which to dissect normal thymocyte development.
Studying the effect on thymocytes at a single time
point after long-term GsA treatment has identified
subsets that are downstream of CsA-sensitive pop-
ulations and the extent to which they are sensitive.
Most conspicuously, the development of mature SP
thymocytes is greatly inhibited (Gao et al., 1988;
Jenkins et al., 1989) leading to atrophy of the
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medulla (Kai and Franklin, 1983; Kanariou et al.,
1989).
It is reported that thymocytes bearing T-cell re-
ceptor V]/-segments (TCRs) reactive with self-
superantigens become detectable amongst mature
thymocytes (Gao et al., 1988; Jenkins et al., 1989),
and in the periphery (Urdahl et al., 1992), where
they could potentially mediate an autoimmune re-
sponse. Such cells (Abe et al., 1988; MacDonald et
al., 1988; Pullen et al., 1988) are normally elimi-
nated by clonal deletion during thymic development
(Kappler et al., 1987; Fry et al., 1989; Hodes et al.,
1989; Schwartz, 1989), preventing their maturation
and entry into the medulla (Hengartner et al., 1988;
Sha et al., 1988; Hugo et al., 1991a). Clonal deletion
is effected via apoptosis (Jenkinson et al., 1989),
which is typified by morphological changes, and
fragmentation of genomic DNA into multimers of
--180 base-pair units (Wyllie et al., 1984). Immature
thymocytes undergoing apoptosis additionally
down regulate expression of CD4 and CD8, but
retain an intact cell membrane, thereby forming a
population that can be identified by flow cytometry
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(Swat et al., 1991a, 1991b) and followed using
TCR-V]/-specific antibodies (Huby and Goff, manu-
script in preparation).
Experimentally, a condition similar to graft-
versus-host disease can be initiated in young rats
(Glazier et al., 1983; Hess et al., 1985) or mice
(Cheney and Sprent, 1983; Bryson et al., 1989;
Sakaguchi and Sakaguchi, 1989) by treating them
with CsA after lethal irradiation and bone marrow
reconstitution, and then withdrawing the drug.
The disease can be initiated in secondary irradiated
hosts by the transfer of peripheral T cells or
thymocytes from these animals (Sorokin et al.,
1986; Beschorner et al., 1988a), or from the thy-
mus of nonirradiated but CsA-treated donors (Sak-
aguchi and Sakaguchi, 1988). This suggests that
CsA induces the generation of autoreactive thymo-
cytes that are exported to the periphery while the
drug is still being administered (Wodzig et al.,
1991) and can initiate an autoimmune reaction
when it is withdrawn. The cells responsible for
such CsA-induced autoimmunity are likely to be
polyclonal, and directed toward true self-antigens
conventionally presented by MHC. In contrast,
superantigen-reactive cells express specific TCR-V]/
segments that recognize superantigen bound to
MHC class II outside the antigen-binding groove
(Dellabona et al., 1990; Choi et al., 1992). The
latter are attractively simple to study, although
their behavior may not necessarily reflect that of
conventional antigen-responsive cells.
It has been speculated that the inhibition of
mature thymocyte development occurs during the
CD4 CD8 (double-positive) stage; however, by
observing subsets at a single time point after CsA
treatment, it is not possible to confirm this. We have
studied the kinetics of thymocyte subsets in the
presence of CsA, using three-color flow cytometry
as a means of pinpointing multiple stages of thy-
mocyte development. In addition, three-color flow
cytometry in this study has enabled the fate of
TCR-V83
/ thymocytes to be followed, these cells
normally being subject to deletion by Mtv-6 in
BALB/c mice (Abe et al., 1988; MacDonald et al.,
1988; Pullen, et al., 1988).
A kinetic study not only allows CsA-sensitive
subsets to be identified, but also reveals the time
taken for a subset to develop from its CsA-sensitive
precursor (Fig. 1, point a). Thus, the faster a subset
is derived from a CsA-sensitive precursor, the more
rapidly it will be lost during treatment. In addition,
the initial rate at which a subset is lost, once its
d
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FIGURE 1. Representation of a kinetic study on the effect of
CsA on a thymocyte subset. The time taken to reach point a, the
point of decline in cell number, indicates the temporal proximity
of the subset to its CsA-sensitive precursor. The gradient of point
b, the initial loss of cells from the subset, indicates the rate of flux
into that subset. Fluctuation in the size of the subset, point c,
indicates heterogeneity within that subset. The size of the subset
,remaining, point d, indicates the limit of depletion of the subset
and is a measure of the efficacy of the CsA treatment.
immediate precursor has been blocked, will be equal
to the rate of flux into that subset (Fig. 1, point b).
Heterogeneity of the subset will be reflected by a
nonlinear loss of cells with time (Fig. 1, point c) and
the size of the subset remaining will be a measure of
the efficacy of the CsA treatment (Fig. 1, point d).
The interpretation of these results requires that
the effects of CsA on specific thymocyte subsets are
direct. Although CsA can affect the thymic microen-
vironment, histological studies have shown such
changes to occur relatively slowly, and therefore
unlikely to account for CsA’s effect on thymocytes.
A kinetic study is again advantageous, demonstrat-
ing that different thymocyte subsets respond to CsA
over very different times spans, an unlikely result if
CsA were acting though a common toxic effect, or
through effects on the thymic stroma.
Here we show that the development of the most
mature CD4 CD8
/CD3high cortical thymocytes is
inhibited by CsA and that CD4 and CD8 SP cells are
not symmetrically derived from CsA-sensitive DP
precursors. Also, among mature CD8 SPs, two
subpopulations with distinct sensitivity to CsA are
revealed and they are distinguishable by expression
of CD45RA. The apoptosis of TCR-V]/3 thymo-
cytes is partially inhibited by CsA, but this does not
permit TCR-V]/3 to mature.CSA AND THYMOCYTE DEVELOPMENT 119
MATERIALS AND METHODS
Mice
Female BALB/c (Mtv-6 /) and B10.D2 (Mtv-6-)
mice were obtained from ICRF, and used when 6-8
weeks old. CsA (Sandimmun; Sandoz UK Ltd.,
Leeds) at 50 mg/ml was dissolved at 1 mg/ml in
0.9% saline, and given I.P. at 10 mg/kg/day as
appropriate. Controls received saline only. Three
animals were used per time point.
Antibodies
CD3CD45RA-, and CD3CD45RA /. Of these, only
CD3- 45RA
/ thymocytes do not occur in measur-
able numbers in vivo (Goff and Huby, 1992). The
size of the other subsets was determined by cross-
correlation as follows: Total CD4 8
/ was deter-
mined from double staining for CD4 and CD8. By
using triple staining and gafing on CD4-8
/ cells,
the fraction bearing CD45RA and CD3, respectively,
was determined directly for appropriately stained
samples. Cells not accounted for by either the
CD45RA
/ subset or the CD3- subset were taken to
be CD3 CD45RA-.
Conjugated antibodies used were anti-CD4-PE and
CD8-FITC (Becton-Dickinson, Oxford, UK); anti-
CD3 (a-chain)-biotin and anti-TCR-V]/3-biotin (both
from PharMingen, San Diego); anti-CD45RA anti-
body RA3-2C2 (ATCC) was purified from cell cul-
ture supernatant using an anti-rat Ig-Sepharose
column and biotinylated using standard procedures.
Staining and Flow Cytometry
Thymocytes were obtained by teasing freshly ex-
cised organs in 5 ml of cold phosphate-buffered
saline (PBS) containing 1% bovine serum albumin
(BSA) and 0.1% sodium azide. Total thymocyte
counts were estimated using a haemocytometer,
using trypan blue to exclude dead cells. Three-color
staining of 1 x 106 cells to reveal CD4, CD8 and
CD3, CD45RA, or TCRV]/3 was carried out by
incubation with a cocktail of the appropriate conju-
gated antibodies, followed by Streptavidin-
Cychrome (PharMingen). Cells were washed twice
in suspension buffer between incubations, which
were of 30-60 min. each, carried out on ice. After
staining, cells were washed and then fixed in 1%
formaldehyde in PBS. Single- and double-color
staining controls were carried out for the purposes
of color compensation as appropriate. A FACScan
cytometer (Becton-Dickinson) with FACScan soft-
ware was used to analyze 10,000 cells per test.
Debris and erythrocytes were eliminated during
acquisition by using a generous forward/side scatter
dot-plot gate that included apoptotic cells.
Flow Cytometric Analysis by Cross-Correlation
Four possible subsets of CD4-8
/ thymocytes can
be defined according to their coexpression of CD3
and CD45RA; CD3CD45RA-, CD3CD45RA/,
Analysis of Flow Cytometric Dot Plots
From samples triple-stained for CD4, CD8, and
TCR-V]/3, 1,000 TCR-V83
/ events were displayed
on dot plots of CD4 vs TCR and CD8 vs TCR.
Images were captured as black-and-white drawings
at 100 dots per inch using a Hewlett-Packard Scan-
jet II-c scanner, and analyzed using Deskpaint 3.20
and Image 1.47 software run on a Macintosh IIsi.
Captured images were blurred by Convoluting with
15 x 15 gaussian smoothing and a preset intensity
threshold applied to distinguish a discrete subset of
apoptotic cells. Calculation revealed the angle to
horizontal of the best-fit oval encompassing this
subset.
RESULTS
Stages of Thymocyte Maturation Inhibited
by CsA
Treatment of BALB/c mice with CsA at 10 mg/kg/
day for 23 days was found to be effective in ablating
the majority of CD4 SP and about half of the CD8
SP thymocytes (Fig. 2). Further subsetting was
possible by detecting CD3 as a third color parame-
ter. Numbers of CD4- CD8- CD3- (triple-negative)
and CD4-CD8- intermediates were moderately
and slowly reduced during treatment, suggesting
that intrathymic precursors with limited capacity for
self-renewal were partially depleted over the period
of the experiment (Fig. 3a). Nevertheless, numbers
of their CD4
/ CD8
/ progeny fell by ---50% within 4
days to a level that was subsequently maintained
(Fig. 3b). Within the DP subset, numbers of CD3high
thymocytes fell rapidly within 2 days of commenc-
ing treatment and thus represented the most CsA-
sensitive subset within the thymus, indicating that120 R.D.J. HUBY et al.
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FIGURE 2. The effect of long-term CsA treatment on thymocyte subsets defined by CD4 and CD8 expression. Numbers show
percentage of cells in subsets defined by the quadrants shown for a representative individual. 1,000 events are displayed.
development from their immediate precursors was
inhibited (Fig. 3b).
CsA had an immediate effect on the number of
CD4 SP thymocyte, with numbers dropping expo-
nentially, consistent with CsA inhibiting the gener-
ation of their immediate CD4 + CD8 + CD3high
precursors (Fig. 3c). Numbers of CD8 SP thymo-
cytes, however, do not drop over the first 2 days
(Fig. 3c). This implies that differentiation of their
immediate precursors (also CD4
/CD8
/CD3high
thymocytes) is insensitive to CsA, whereas that of
an earlier precursor---2 days "upstream" is sensi-
tive. The loss of mature CD8 SP thymocytes was
biphasic, owing to a heterogeneity that could be
distinguished according to CD45RA expression;
CD45RA- cells disappeared rapidly after an initial
2-day lag whereas CD45RA cells were unaffected
by CsA for the first 10 days of treatment, after
which their numbers declined rapidly (Fig. 3d).
By gating on CD3high thymocytes, cells in transit
from the CD4+CD8
/ to the CD4 and CD8 SP
subsets can be demonstrated (Fig. 4). Consistent
with this analysis, the CD4 SPs, but not CD8 SPs
were discrete from the CD4
/ CD8
/ subset after 2
days of CsA treatment (cf. Fig. 3c). The CD8 SP
subset was discrete by day 7, before the numbers of
CD8
/CD45RA
/ thymocytes had started to decline
(Fig. 3d), indicating that the latter were not directly
derived from this DP subset.
CsA Inhibits the Apoptosis of Autoreactive
Thymocytes
Immature thymocytes undergoing apoptosis down-
regulate CD4 and CD8 expression (Swat et al.,
1991a, 1991b), and this phenomenon can be ob-
served amongst TCR-Vfl3
/ thymocytes in vivo as a
response to Mtv-6 (Huby and Goff, manuscript in
preparation). This causes an increase in the propor-
tion of CD4dimCD8dim thymocytes (Fig. 5), but
quantification of their relative numbers is arbitrary
and insensitive. We have found that down-
regulation of CD4 and CD8 is concomitant with
up-regulation of T-cell receptor, producing a char-
acteristic profile for TCR-Vfl3
/ cells in dot plots of
Vfl3 vs CD8 and Vfl3 vs CD4 (Fig. 5). Here, this
profile was quantified using an image analysis pro-
gram, as described in Materials and Methods. A
single dose of CsA at 10 mg/kg led to a maximal
effect on the apoptotic phenotype of TCR-Vfl3
/
immature thymocytes within 24 hours of adminis-
tration. Thus, the angle corresponding to down-CSA AND THYMOCYTE DEVELOPMENT 121
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FIGURE 3. Progressive effect of CsA on the mean size of thymocyte subsets defined by triple staining for CD4, CD8, and
CD3/CD45RA. 3 animals per time point. Note different vertical scales have been used, and note particularly that numbers for
CD4+CD8+CD3high thymocytes have been multiplied by 10 to fit the same scale as total CD4+CD8 thymocytes. Error
bars + S.E.M.
regulation of CD8 among developing thymocytes corresponding to a greater level of maturity; the
up-regulating TCR-V/3 was reduced by 62% overall fraction of cells with a CD4dimCD8
dim phe-
(p- 0.012), and that corresponding to down- notype was therefore unaffected (Fig. 5).
regulation of CD4 by 30% (p 0.005) (Fig. 5 and 6).
Similar results were seen for as long as CsA was Mature Autoreactive Thymocytes Fail to
given (Fig. 6). Within 3 days of ceasing injections,
however, the apoptotic phenotype of TCR-V]/3
/ Develop in CsA-Treated Mice
thymocytes was restored (p 0.14 and p--0.53 for Using three-color staining, we determined the fre-
CD4 and CD8 angles respectively, compared to quency of TCR-V83
+ cells within subsets defined
untreated controls, Fig. 6). It should be noted that by CD4 and CD8, during CsA treatment. The
with CsA treatment, TCR-V83
+ thymocytes did fraction of thymocytes expressing TCR-V//3 was
ultimately develop a CD4aimcD8aim phenotype, al- unaffected by CsA, the vast majority expressing low
beit when they expressed higher levels of TCR, levels of this antigen, and belonging to the DP122 R.D.J. HUBY et al.
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FIGURE 4. Do plots showing changes in the distribution of CD3high thymocytes within subsets defined by CD4 and CD8 after
various periods of CsA treatment. The number of events displayed is proportional to the fraction of thymocytes expressing high levels
of CD3; high is defined as the level expressed by CD3 SP thymocytes in control animals.
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FIGURE 5. Effect of CsA on the down-regulation of CD4 and CD8 on TCR-V/Y3 thymocytes undergoing apoptosis induced by
Mtv-6. Arrows show the approximate angle measured in each case in order to quantify the apoptotic phenotype. 1,000 events per
plot are displayed. Numbers within dot plots represent the percentage of cells within the corresponding subpopulation.
subset (data not shown). Absolute numbers of
TCR-V,83 thymocytes dropped for all subsets, par-
ticularly the mature SPs (Fig. 7). Thus, after 23 days
of CsA, fewer than 6,000 mature TCR-V,83 SP
cells per thymus were estimated to be present.
DISCUSSION
Using three-color flow cytometry to analyze the
kinetics of thymocytes treated in vivo with CsA, we
have been able to define more specifically theCSA AND THYMOCYTE DEVELOPMENT 123
thymocyte subsets that are affected by this drug and
to determine the relationships between subsets and
CsA-sensitive stages of development. We have
found that numbers of early thymocytes, belonging
to the CD4-CD8-CD3- subset (Crispe et al., 1987;
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FIGURE 6. Inhibition of the apoptotic phenotype by CsA. Bars
represent the mean angle of the TCR-V]/3 subset to horizontal, as
demonstrated in Fig. 4, for 3 to 6 mice per group. Grey vs. CD4;
hatched vs. CD8; error bars + S.E.M.; 3d recov. thymocytes
from mice treated with CsA for 18 days and then untreated for 3
days. To facilitate quantification of this subset in B10.D2 (Mtv-6
control mice, SP thymocytes were first gated out.
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FIGURE 7. Progressive effect of CsA on mean numbers of
TCR-V]/3 SP cells per thymus. Solid line CD4 SP; dotted
line CD8 SP; error bars + S.E.M.
Scollay et al., 1988) and their immediate
CD4 CD8 CD3 progeny (Shortman et al., 1988)
decline slowly in the presence of CsA. This is
consistent with previous results showing that pre-
prothymocytes are sensitive to CsA (Huby et al.,
1989), and that intrathymic prothymocytes have a
large but limited capacity for self-renewal (Frey et
al., 1992). CD4 CD8 CD3
/ thymocytes, thought
to constitute a side lineage with a slow turnover
(Egerton et al., 1990) and a CsA-sensitive precursor
(Takahama et al., 1991), declined with very similar
kinetics to CD4-CD8-CD3- thymocytes (unpub-
lished data).
In BALB/c mice, about 50% of the CD4
/ CD8
subset was lost within 4 days of commencing CsA
treatment, primarily accounting for a similar loss of
thymic weight over the same period. Placebo-
injected controls were essentially unaffected (data
not shown). Within the CD4
/ CD8
/ subset, the
CD3high fraction underwent very rapid depletion,
falling to minimal levels within 2 days. Such a rapid
decline indicates that this subset is very transient,
as described elsewhere (Hugo et al., 1991b), and
that its immediate precursors are CsA-sensitive.
It has been suggested elsewhere that the
CD4
/ CD8
/ CD3high subset is the immediate prog-
eny of CD4
/ CD8
/CD3lw cells (Penit, 1990; Hues-
mann et al., 1991). CsA must also partially block the
development of DPs further upstream to account for
a loss of over half these cells by day 4 after the start
of treatment. CsA therefore may inhibit partially the
development of CD4 CD8 thymocytes from ear-
lier precursors, or it may affect the kinetics of cell
development within that subset.
Because most CD4
/CD8
/ CD3high thymocytes do
not survive CsA treatment and this subset contains
the immediate precursors of SP thymocytes (Hugo
et al., 1991b), it can be predicted that CsA should
cause a relatively rapid loss of SP thymocytes, by
preventing the generation of this subset. This expla-
nation is feasible for CD4 SP thymocytes, because
the subset shrank rapidly when CsA was adminis-
tered, and lost continuity with the CD4 /CD8
CD3high subset. The CD8 SPs, however, did not
respond in this way for about 2 days, implying that
it is the differentiation of their somewhat distant
(rather than immediate) precursors that is inhibited
by CsA. This implies that CD4 and CD8 SP thymo-
cytes are not symmetrically derived from a common,
CsA-sensitive precursor.
In BALB/c, there are two major subsets of
CD8
/ CD3
/ thymocytes that can be distinguished124 R.D.J. HUBY et al.
according to the expression of CD45RA. The
CD45RA
/ subset, accounting for---50% of the CD8
SPs, are essentially absent from some strains, such
as C57BL/6 (Huby and Goff, 1992). They represent
an additional subset when they are present (Goff
and Huby, 1992), that is, there is no corresponding
loss of CD45RA- cells. The CD45RA
/ (8RA) subset
was found to respond to CsA with unusual kinetics;
their numbers were unaffected for 10 days, after
which they showed a rapid decline. This suggests
that there is normally a significant flux of cells into
the 8RA subset and that it is distantly derived from
a CsA-sensitive precursor. The identity of this (and
of their immediate) precursors remains enigmatic;
the majority of DP thymocytes are too short-lived
(Egerton et al., 1990) to be contenders, and a subset
with such a rapid input of mature cells is unlikely to
be of extrathymic origin. 8RAs may be derived from
CD8
/CD458RA- cells, leading us to speculate that
they may constitute thymic emigrants. However,
intrathymic random cell labeling with FITC has
revealed, as in strains such as CBA/Ca (Kelly and
Scollay, 1990) that have low numbers of 8RAs
(Huby and Goff, 1992), that the recent thymic
emigrants of BALB/c are also CD45RA- (R. Scollay,
personal communication). In B10.D2 mice, which
essentially lack 8RAs, the CD8 SP subset responds
to CsA with kinetics similar to those of the
CD45RA- subset of CD8 SPs of the BALB/c (un-
published data).
CsA treatment can lead to the generation of
autoreactive T cells capable of inducing a graft-
versus-host like disease in immunocompromised
animals (Cheney and Sprent 1983; Glazier et al.,
1983; Hess et al., 1985). Autoreactive T cells can be
found in the thymus of diseased animals (Bes-
chomer et al., 1988b), where they are presumably
generated during CsA treatment, because prior
thymectomy is protective (Sorokin et al., 1986). The
aetiology of the disease, however, may depend
critically upon the destruction of thymic medullary
stroma initiated by CsA-induced cytotoxic T cells
(Beschomer et al., 1988b); T cells capable of recog-
nizing self-superantigens (Kappler et al., 1987,
1988) have been found in the thymus (Gao et al.,
1988; Jenkins et al., 1989) and periphery (Urdahl et
al., 1992) of CsA-treated mice. This has led to the
hypothesis that CsA treatment leads to a general
failure of clonal deletion, allowing such cells to
proceed beyond the immature CD4
/ CD8
/ stage at
which they are normally deleted (Hengartner et al.,
1988; Hugo et al., 1991a), albeit in small numbers
owing to CsA blocking the maturation of SP thy-
mocytes.
Previously, it has been shown that CsA generally
inhibits the ability of immature thymocytes to un-
dergo apoptosis (Shi et al., 1989), the major mech-
anism whereby clonal deletion is achieved
(Jenkinson et al., 1989). Using a flow cytometric
method (Swat et al., 1991a, 1991b), we have dem-
onstrated that CsA specifically affects the develop-
ment of the apoptotic CD4dimcD8dim phenotype
amongst potentially autoreactive TCR-V]/3
/ thymo-
cytes in Mtv-6
/ mice. The loss of CD8, concomitant
with up-regulation of TCR, was more greatly inhib-
ited than that of CD4, and because apoptosis occurs
rapidly, this is likely to reflect active regulation.
Interestingly, it has been found that CsA fails to
block the early phase of CD4 down-regulation
induced by protein kinase C-activation, but effec-
tively blocks CD8 down-regulation (Nakayama and
Nakauchi, 1993). Nevertheless, acquisition of a
CD4dimcD8aim phenotype and population deletion
did ultimately occur for immature TCR-V]/3
/ thy-
mocytes. Essentially, no mature TCR-V]/3
/ thymo-
cytes developed, as determined by three-color flow
cytometry, a method capable of detecting them with
greater accuracy and sensitivity than was possible in
previous studies (Gao et al., 1988; Jenkins et al.,
1989; Urdahl et al., 1992). This suggests that CsA
effectively prevented the maturation of potentially
autoreactive thymocytes that it had permitted to
escape clonal deletion. TCR-V]/3 deleted by Mtv-6,
however, may be unusual in this respect; it is
possible that the deletion of cells reactive to con-
ventional self-antigens may be more effectively in-
hibited by CsA, allowing their maturation into
autoreactive T cells.
To summarize, we find that CsA directly inhibits
the development of CD4+Cd8+CD3high thymo-
cytes. CD4 and CD8 SP thymocytes are derived by
nonidentical pathways from these CsA-sensitive
precursors. The CD45RA
/ subset of CD8 SP thy-
mocytes, present in only some mouse strains, has a
rapid turnover and is derived in about 10 days from
a CsA-sensitive precursor, possibly via the
CD45RA- subset of CD8 SPs. CsA treatment does
not allow the development of TCR-V]/3
/ thymo-
cytes, despite the fact that their apoptosis induced
by Mtv-6 appears to be inhibited. It is now known
that CsA can affect thymocyte function by binding
to cyclophilin, a modulator of calcineurin activity
(Fischer et al., 1989; Takahashi et al., 1989; Liu et
al., 1991). It remains to be determined why CsACSA AND THYMOCYTE DEVELOPMENT 125
blocks thymocyte differentiation at such specific
points of development, although linkage to a re-
quirement for TCR stimulation is emerging as a
possible common theme.
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